Platform Randomised trial of INterventions against COVID-19 In older peoPLE - PRINCIPLE

niversity of Oxford / Clinical Trials and Research Governance0 个研究点目标入组 3,000 人开始时间: 2020年3月25日最近更新: 2020年11月16日

适应症

试验速览

暂无简介。

•Participant is willing and able to give informed consent for participation in the study.
•Participant is willing to comply with all trial procedures
•Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) within 7 days of inclusion
•Patients aged =50-64 years with any of the following listed comorbidities:
•- known weakened immune system due to a serious illness or medication (e.g. chemotherapy)
•- known heart disease
•- known asthma or lung disease
•- known diabetes not treated with insulin
•- known mild hepatic impairment
•- known stroke or neurological problem
•Patients aged =65 with or without comorbidity
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 500
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2500

•Pregnancy
•Breastfeeding
•Known severe hepatic impairment
•Known severe renal impairment
•Known acute porphyrias
•Type 1 diabetes or insulin dependent Type 2 Diabetes mellitus
•Known G6PD deficiency
•Known myasthenia gravis
•Known severe Psoriasis
•Known severe neurological disorders (especially those with a history of epilepsy may lower seizure threshold)
•Previous adverse reaction to, or currently taking, hydroxychloroquine
•Known retinal disease
•Judgement of the recruiting clinician deems ineligibile

发起方

niversity of Oxford / Clinical Trials and Research Governance